TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evogene ( (EVGN) ) has provided an announcement.
Evogene Ltd., an Israeli company, has announced an update regarding its annual general meeting of shareholders scheduled for August 11, 2025. The company has issued a revised proxy card to allow shareholders to vote individually for each director nominee, addressing a previous oversight. This update ensures clarity and consistency for all shareholders, although those voting through Broadridge Financial Solutions or the Tel Aviv Stock Exchange will not be affected by the change.
The most recent analyst rating on (EVGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance, with persistent losses, negative cash flow, and financial instability. Technical indicators show a lack of strong upward momentum, and valuation metrics are unattractive. While strategic efforts in expense reduction and acquisitions are positive, they are overshadowed by significant revenue declines and ongoing financial challenges.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Average Trading Volume: 2,254,263
Technical Sentiment Signal: Sell
Current Market Cap: $10.98M
Find detailed analytics on EVGN stock on TipRanks’ Stock Analysis page.